Organogenesis Holdings Stock-Based Compensation Growth & History (ORGO)

Organogenesis Holdings's stock-based compensation was $13.3M for fiscal 2025.

View full Organogenesis Holdings company overview

Organogenesis Holdings annual stock-based compensation history

Organogenesis Holdings annual stock-based compensation

Fiscal yearPeriod endedStock-based compensationChangeGrowth
20252025-12-31$13.3M$2.7M+25.71%
20242024-12-31$10.6M$1.6M+17.59%
20232023-12-31$9.0M$2.4M+37.30%
20222022-12-31$6.6M$2.7M+69.57%
20212021-12-31$3.9M$2.2M+132.63%
20202020-12-31$1.7M$725,000+77.46%
20192019-12-31$936,000−$139,000−12.93%
20182018-12-31$1.1M$156,000+16.97%
20172017-12-31$919,000$446,000+94.29%
20162016-12-31$473,000

Organogenesis Holdings stock-based compensation trends

Over the last five fiscal years, Organogenesis Holdings's stock-based compensation increased from $1.7M to $13.3M, a change of $11.6M. The latest reported quarter, Q2 2026, shows $3.1M.

About the metric

What stock-based compensation means

Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.

Calculation and source

SEC-reported stock-based compensation

TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Organogenesis Holdings source filings ↗

Community posts

It’s quiet here.

No posts about ORGO yet. Start the conversation.

Write the first post